Metabolic Parkinson's disease

Area of Science:

• Neuroscience
• Metabolic Disorders
• Pharmacology

Background:

• Parkinson's disease (PD) involves dopaminergic neuron loss.
• Growing evidence links PD to metabolic dysfunctions like type 2 diabetes, obesity, and metabolic syndrome.
• Shared pathogenic mechanisms include insulin resistance, inflammation, mitochondrial dysfunction, and gut microbiota changes.

Purpose of the Study:

• To explore the connection between metabolic disorders and Parkinson's disease.
• To investigate potential shared etiological factors and therapeutic strategies.
• To highlight the cross-efficacy of drugs used for both conditions.

Main Methods:

• Review of preclinical and clinical studies on PD and metabolic disorders.
• Analysis of shared cellular damage patterns (mitochondrial dysfunction, oxidative stress, etc.).
• Examination of drug repurposing potential (e.g., metformin, incretin mimetics, bromocriptine).

Main Results:

• Metabolic dysfunctions share cellular damage pathways with PD.
• Antidiabetic drugs (metformin, incretin mimetics) show neuroprotective effects in PD.
• Antiparkinsonian drugs (bromocriptine) improve glycemic control in diabetes.

Conclusions:

• Shared pathogenesis between metabolic disorders and PD is hypothesized.
• Understanding these connections can lead to novel preventive and therapeutic strategies for PD.
• Lifestyle, dietary modifications, and repurposed drugs offer potential disease-modifying approaches.